Aerosolized vancomycin for the treatment of MRSA after lung transplantation.
Lung transplantation is the only life-prolonging therapy available for cystic fibrosis (CF) patients with end-stage lung disease. The presence of pathogens in the airways of CF patients prior to transplantation is the major risk factor for infection in the post-transplantation period, with methicillin-resistant Staphylococcus aureus (MRSA) having a growing impact. Aerosolized vancomycin has been used successfully in the treatment of MRSA in the CF population but its use after lung transplantation has not been previously reported. We report the case of a lung transplant recipient who was successfully treated for MRSA infection with aerosolized vancomycin.
Hayes
Don
D
Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky 40536,, USA. don.hayes@uky.edu
Murphy
Brian S
BS
Mullett
Timothy W
TW
Feola
David J
DJ
D000280:Administration, Inhalation; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003550:Cystic Fibrosis / Q000601:surgery*; D006801:Humans; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014640:Vancomycin / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D014640:Vancomycin